Walters announces signing bonuses for rural Oklahoma teachers, despite past controversy
Recent Quotes
My Watchlist
Indicators
Local Stocks
NewsOK Local Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

41.20 -0.28 (-0.68%)
Official Closing Price Updated: 7:00 PM EDT, Jun 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 14,271,434
Open 41.41
Bid (Size) 41.25 (1)
Ask (Size) 41.28 (5)
Prev. Close 41.48
Today's Range 40.75 - 41.86
52wk Range 39.91 - 66.38
Shares Outstanding 2,222,113,553
Dividend Yield 5.53%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
3 High-Yield S&P 500 Dividend Stocks Down More Than 25% to Buy Now and Hold for at Least a Decade
Their prices might not be done falling, but you can count on the dividends they distribute to continue rising steadily. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 High-Yield Dividend Stocks for Income Now and Growth Later
Buying high-yield dividend stocks at a low price today gives you current income with the opportunity for growth when interest rates come down later this year 
Via MarketBeat
Topics Economy
Exposures Interest Rates

Performance

YTD
-21.91%
-21.91%
1 Month
-6.60%
-6.60%
3 Month
-20.14%
-20.14%
6 Month
-19.75%
-19.75%
1 Year
-37.73%
-37.73%

More News

Read More
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
From Bristol Myers Squibb
Via Business Wire
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
Via Benzinga
Smart Money Is Betting Big In BMY Options
Via Benzinga
6% Yield Bristol Myers Squibb Value Trap Or Long-Term Opportunity?
Via Talk Markets
3 Penny Stocks to Buy if You Want to Spend Less and Earn More
Via InvestorPlace
7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too)
Via InvestorPlace
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million
Via Talk Markets
The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024
Via InvestorPlace
Bristol-Myers Squibb's Options: A Look at What the Big Money is Thinking
Via Benzinga
FDA Approves Geron's First Commercial Drug, Competes With Bristol Myers Squibb's Blood Cancer Drug
Via Benzinga
Exposures Product Safety
Why Is Mid-Cap Cancer-Focused Replimune Stock Trading Higher On Thursday?
Via Benzinga
Bristol Myers Squibb Announces Phase 3 Results Of Opdivo/Yervoy Combo In Liver Cancer Patients
Via Benzinga
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Why US Drug Giant Bristol Myers Squibb Stock Trading Up On Monday
Via Benzinga
Bristol Myers Squibb’s Breyanzi Demonstrates Clinically Meaningful Outcomes Across Broad Range of B-Cell Malignancies in New Data Presented at 2024 ASCO® Annual Meeting
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Presents Multiple New Analyses at 2024 ASCO® Annual Meeting Highlighting Opdivo and Opdivo-based Combinations in Early and Advanced Stages of Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
2 No-Brainer Dividend Stocks You Can Buy With $100 in June
Via The Motley Fool
KRAZATI (adagrasib) Demonstrated Statistically Significant Improvement in Progression-Free Survival in Patients with Pretreated Locally Advanced or Metastatic KRASG12C-Mutated Non-Small Cell Lung Cancer
From Bristol Myers Squibb
Via Business Wire
FDA Expands Approval For Bristol Myers Squibb's Breyanzi, Making CAR T Cell Therapy Available For Broadest Range Of B-Cell Malignancies
Via Benzinga
Exposures Product Safety
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
U.S. Food and Drug Administration Approves Bristol Myers Squibb’s Breyanzi as a New CAR T Cell Therapy for Relapsed or Refractory Mantle Cell Lymphoma
From Bristol Myers Squibb
Via Business Wire
7 Underappreciated Stocks With 25% Return Potential in 2024
Via InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.